Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. (Q53568928)

15 May 2018

title

Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. (English)

1 reference

15 May 2018

author

Francesco Bertoni

8

1 reference

15 May 2018

Gianluca Gaidano

6

object named as

Gianluca Gaidano

1 reference

15 May 2018

Katia Lacrima

1

1 reference

15 May 2018

Andrea Rinaldi

2

1 reference

15 May 2018

Sara Vignati

3

1 reference

15 May 2018

Vittoria Martin

4

1 reference

15 May 2018

Maria Grazia Tibiletti

5

1 reference

15 May 2018

Carlo V Catapano

7

1 reference

15 May 2018

publication date

1 January 2007

1 reference

15 May 2018

published in

Leukemia & Lymphoma

1 reference

15 May 2018

volume

48

1 reference

15 May 2018

issue

1

1 reference

15 May 2018

page(s)

158-167

1 reference

15 May 2018

Molecular pathogenesis of diffuse large B-cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Cell cycle deregulation in B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

CDK inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q21) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Cell-type-specific responses to chemotherapeutics in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

E2F4 deficiency promotes drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190601026562

10.1080/10428190601026562

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

17325859

1 reference

15 May 2018